Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 10, 2025

Objective This study aims to evaluate the hemorrhage risk in solid tumor patients receiving angiogenesis inhibitors (AGIs), immune checkpoint (ICIs), and their combination using FDA Adverse Event Reporting System (FAERS) database. Methods Data from Q1 2011 Q4 2023 were extracted FAERS database for treated with AGIs, ICIs, or combination. A disproportionality analysis was conducted by calculating reporting odds ratio (ROR) corresponding 95% confidence interval (CI), as well Proportional Ratio (PRR), identify potential safety signals. To assess whether is higher therapy compared monotherapy, additive multiplicative models employed interactions between single-agent treatments. Results The of AGIs ICIs significantly increased hemorrhagic adverse events, particularly pulmonary hemorrhage. Hemorrhagic events common females (50.97%) older (aged 64+), frequently occurring within first 30 days treatment (38.11%). Gingival (ROR 3, PRR 418.9) 9.65, 1893.36) most AGI group, while 9.49, 1350.78) 2.6, 98.97) prominent ICI group. In esophageal variceal 40.72, 2344.72) 19.31, 1056.63) exhibited risks Additive indicated that excess (RD AB = 0.01025, P<0.001) relative (RR 1.99277, than those suggesting a positive interaction drugs further increases Conclusion Our demonstrates raises hemorrhage, underscoring urgent need enhanced monitoring protocols clinical practice improve efficacy safety.

Language: Английский

---

Challenges and opportunities in single-domain antibody-based tumor immunotherapy

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 189284 - 189284

Published: Feb. 1, 2025

Language: Английский

---

Combination therapy with alisertib enhances the anti-tumor immunity induced by a liver cancer vaccine

iScience, Journal Year: 2025, Volume and Issue: 28(4), P. 112120 - 112120

Published: March 15, 2025

Alisertib is a potent aurora A kinase inhibitor in clinical trials for cancer treatment, but its efficacy on vaccines remains unclear. Here, we developed DNA vaccine targeting glypican-3 (pGPC3) and evaluated with alisertib hepatocellular carcinoma (HCC) models. The combination therapy of pGPC3 significantly inhibited subcutaneous tumor growth, enhanced the induction maturation CD11c+ CD8+CD11c+ dendritic cells (DCs), expanded tumor-specific CD8+ T cell responses. depletion abolished anti-tumor effects, underscoring essential role functional Moreover, combined treatment promoted memory induction, providing long-term protection. In liver orthotopic models, demonstrated therapeutic through These results indicate that enhances vaccine's effect, offering promising strategy HCC treatment.

Language: Английский

---

RNF2 induces myeloid-derived suppressor cells chemotaxis and promotes hepatocellular carcinoma progression through the TRAF2-NF-κB signaling axis

Cancer Immunology Immunotherapy, Journal Year: 2025, Volume and Issue: 74(5)

Published: March 27, 2025

Language: Английский

---

Next‐Generation Flexible Embolic Systems: Targeted Transarterial Chemoembolization Strategies for Hepatocellular Carcinoma

Advanced Materials, Journal Year: 2025, Volume and Issue: unknown

Published: April 7, 2025

Abstract Transarterial chemoembolization (TACE) remains the gold standard for treating intermediate‐stage hepatocellular carcinoma (HCC), yet faces great challenges in overcoming tumor heterogeneity, hypoxia‐induced angiogenesis, and metastatic progression. The development of advanced flexible embolization materials marks a revolutionary leap interventional therapy, offering opportunities to revolutionize precision, drug delivery kinetics, microenvironment modulation. This comprehensive review systematically examines paradigm shift toward next‐generation TACE technology, emphasizing limitations conventional approaches innovations embolic agents. A detailed discussion nano‐flexible systems is presented, their unique coagulation dynamics, real‐time imaging capabilities, therapeutic precision. delves into groundbreaking strategies integrating hypoxia modulation, energy conversion therapeutics, sophisticated engineering. Clinical translation aspects are thoroughly explored, including large‐scale trial outcomes, vascular recanalization patient‐specific treatment optimization. Looking forward, key frontiers field identified: intelligent nanocomposite systems, synergistic combination therapies, precision medicine tailored individual biology. work not only objectively evaluates current progress but also charts future research priorities, aiming transform from palliative intervention platform ultimately reshaping landscape HCC patient care.

Language: Английский

---

Comparative efficacy of interventional therapy with or without targeted immunotherapy in Child-Pugh B hepatocellular carcinoma patients: a single-center, retrospective study

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: May 1, 2025

Background Current large clinical trials mainly focus on Child-Pugh A (CP-A) stage hepatocellular carcinoma (HCC) patients, with limited data CP-B patients especially those classified as B8-9, whose treatment needs remain inadequately addressed. This study aims to evaluate the safety efficacy of interventional treatments, or without targeted-immunotherapy and characteristics HCC receiving. Methods single-center retrospective investigation incorporated 119 were stratified into two cohorts: therapy cohort (42) combined targeted immunotherapy (77). The data, overall survival (OS), progression-free (PFS), therapeutic both groups meticulously recorded comprehensively analyzed. Survival disparities statistically compared employing Kaplan-Meier analysis method log-rank test. Tumor remission was appraised in accordance RECIST 1.1 mRECIST criteria. Independent influencing factors discerned through multifactorial COX regression analysis. Subsequently, prediction models constructed generate column line graphs, profiles adverse events associated diverse modalities also evaluated. Results grade included, median (mOS) who received combination 21.4 months (vs 13.2, P=0.038) superior that therapy, (mPFS) 12.7 10.9 months, P=0.183) not significantly improved. OS group B7 24.6 11.9, P=0.006) intervention, while there no significant improvement B8-9. objective rate (ORR) higher than intervention (RECIST: 32.5% vs 11.9%, P = 0.014; mRECIST: 48.1% 23.8%, 0.010). Except for score progression (P 0.003), difference occurrence all-grade ≥grade 3 > 0.05). Conclusion Interventional can be a safe effective B setting controlled liver function impairment.

Language: Английский

---

Anti-Cancer Drugs: Trends and Insights from PubMed Records

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(5), P. 610 - 610

Published: May 4, 2025

Background: In recent years, there has been an exponential growth in global anti-cancer drug research, prompting the necessity for comprehensive analyses of publication output and thematic shifts. Methods: This study utilized a set PubMed records from 1962 to 2024 examined patterns, content classification, co-occurrence key pharmacological molecular terms. Results: Our results highlight rise publications, with annual compound rate over 14%, influenced by advancements digital knowledge sharing novel therapeutic breakthroughs. A pronounced surge occurred during COVID-19 pandemic, suggesting sustained shift research dynamics. The revealed strong emphasis on classical chemotherapeutic agents—often studied combination targeted therapies or immunotherapies—and growing focus immune checkpoint inhibitors vaccine platforms. Furthermore, networks indicated robust links between chemotherapy supportive care, as well emerging synergies immuno-oncology, precision medicine approaches. Conclusions: suggests that while modalities are reshaping treatment paradigms, remains central, underscoring value integrative regimens. trend toward personalized, combination-based strategies indicates transformative era oncology where multidimensional data assessment is instrumental guiding future innovations.

Language: Английский

---

Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(24), P. 13590 - 13590

Published: Dec. 19, 2024

Systemic therapy for unresectable hepatocellular carcinoma (HCC) has progressed with the development of multiple kinases, such as vascular endothelial growth factor (VEGF) signaling, targeting cancer and angiogenesis. Additionally, efficacy sorafenib, regorafenib, lenvatinib, ramucirumab, cabozantinib been demonstrated in various clinical trials, they are now widely used practice. Furthermore, effective immune checkpoint inhibitors systemic HCC, atezolizumab + bevacizumab (atezo/bev) durvalumab tremelimumab recommended first-line treatment. Atezo/bev therapy, which combines an anti-programmed cell death 1 ligand antibody anti-VEGF antibody, is first immunotherapy to demonstrate against HCC. With increasing popularity these treatments, VEGF inhibition attracting attention from perspective its anti-angiogenic effects impact on cancer-immune cycle. In this review, we outline role tumor microenvironment cycle HCC potential regulatory mechanisms VEGF. consider significance dual angiogenesis immune-related molecules by VEGF, ultimately aim clarify latest treatment strategies that maximizes efficacy.

Language: Английский

---

Advances on the role of stem cells in liver cancer

Deleted Journal, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 12

Published: Dec. 31, 2024

Liver cancer, especially hepatocellular carcinoma (HCC), is one of the most common malignant tumors worldwide, and its high mortality rate treatment difficulty have always been major challenges faced by medical community. With continuous development biotechnology, stem cell research has shown great potential hope in liver cancer treatment. This review provides a brief overview importance cells research, including identification (LCSCs), molecular maintenance mechanisms stemness LCSCs, targeted therapy strategies, as well therapy, proposing future directions.

Language: Английский

---